Fair Value - Additional Information (Details) $ in Thousands				1 Months Ended				3 Months Ended		6 Months Ended		12 Months Ended
	Apr. 22, 2024 USD ($) Milestone payment	Jul. 31, 2023 USD ($) Installment	Apr. 07, 2022	Oct. 31, 2024 USD ($)	Jul. 31, 2024 USD ($)	Apr. 30, 2024 USD ($) Installment	Apr. 30, 2022 USD ($) Installment	Jun. 30, 2024 USD ($) shares	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) shares	Jun. 30, 2023 USD ($)	Dec. 31, 2018 USD ($) Installment shares	Nov. 21, 2022 shares
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Number of milestone payments remaining | Milestone payment	1
Remaining milestone payment	$ 6,100
Milestone payment due date	Oct. 01, 2024
Change in fair value of warrant liability											$ (61)
Loss on debt extinguishment								$ (248)		$ (248)
2018 Notes | Series G Preferred Stock
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant issued to purchase shares | shares								613,333		613,333
Contingent Consideration
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest expense due to passage of time and fixed payment schedule								$ 200	$ 1,000	$ 900	2,100
Loss on debt extinguishment								200
Contingent Consideration | Subsequent Event | Third Amendment to APA Agreement
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Milestone payment					$ 8,400
Warrant Liabilities
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant issued to purchase shares | shares													5,000,000
Change in fair value of warrant liability								$ 0	$ 0	$ 0	$ 100
Integrated Diagnostics, Inc
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Prepaid milestone payment	$ 8,400
Integrated Diagnostics, Inc | Contingent Consideration
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business acquisition description										requires additional consideration to be paid by the Company to such shareholders upon attainment of a three-consecutive month
Business acquisition contingent consideration gross margin target												$ 2,000
Business acquisition contingent consideration gross margin target period												7 years
Integrated Diagnostics, Inc | Contingent Consideration | Third Amendment to APA Agreement
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration number of installments | Installment		3				1	5
Milestone payment		$ 3,000				$ 5,000	$ 2,000
Percentage of interest on installment payments			10.00%
Integrated Diagnostics, Inc | Contingent Consideration | Scenario Forecast | Third Amendment to APA Agreement
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Exit fee payment				$ 6,100
Integrated Diagnostics, Inc | Common Stock | Contingent Consideration
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business acquisition description										If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in two equal and consecutive quarterly cash installments totaling $37.0 million.
Contingent consideration shares | shares												2,520,108
Contingent consideration number of installments | Installment												8
Contingent consideration arrangements, common shares, redemption amount										$ 4,600		$ 37,000
Repayments of debt										9,300
Business combination contingent consideration final payment										$ 37,000
Contingent consideration cash payment												$ 37,000
Investment, Type [Extensible Enumeration]												Repurchase [Member]
Minimum | Contingent Consideration
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range										11.00%
Maximum | Contingent Consideration
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range										16.00%